Mustafa Duran1, Murat Ziyrek1, Yakup Alsancak2. 1. Department of Cardiology, Konya Education and Research Hospital. 2. Meram Medical Faculty, Department of Cardiology, Necmettin Erbakan University, Konya, Turkey.
Abstract
BACKGROUND: According to EMPA-REG OUTCOME, trial use of empagliflozin in patients with a history of cardiovascular disease improves hospitalization for heart failure and decreases cardiovascular morbidity and mortality. Recent studies have shown that a prolonged T-peak to T-end interval on the resting electrocardiography is associated with an increased risk of cardiovascular mortality. Tp-e/corrected QT interval (QTc) ratio is a reliable index of prolonged ventricular repolarization. OBJECTIVES: In this study, we examined the effects of sodium glucose co-transporters 2 (SGLT2) inhibitors as an add-on therapy to metformin on electrocardiographic indices of ventricular repolarization. METHODS: Electrocardiographic recordings before combination therapy along with three months and six months follow-up of 141 consecutive patients who were switched from monotherapy to combination therapy with two oral agents due to inadequate glycemic control were derived. QT interval (QT), QTc, Tp-e intervals and Tp-e/QT, Tp-e/QTc ratios were calculated and analyzed. RESULTS: After the six month follow-up, there was a significant decrease in the QT interval in patients who were using SGLT2 inhibitors as an add-on therapy to metformin compared to other glucose-lowering agents (373.4 ± 9.9 ms vs. 385.4 ± 12.5 ms, 382.9 ± 11.2 ms; p < 0.001 respectively). Furthermore, Tp-e/QT and Tp-e/QTc ratios were significantly lower in this patient population compared to control groups (0.186 ± 0.023 vs. 0.196 ± 0.021, 0.191 ± 0.017; p < 0.001 and 0.174 ± 0.021 vs. 0.199 ± 0.022, 0.195 ± 0.016; p < 0.001 respectively). CONCLUSIONS: Our data showed that using SGLT2 inhibitors as an add-on therapy to metformin favorably alters ventricular repolarization indices in patients with type 2 diabetes mellitus.
BACKGROUND: According to EMPA-REG OUTCOME, trial use of empagliflozin in patients with a history of cardiovascular disease improves hospitalization for heart failure and decreases cardiovascular morbidity and mortality. Recent studies have shown that a prolonged T-peak to T-end interval on the resting electrocardiography is associated with an increased risk of cardiovascular mortality. Tp-e/corrected QT interval (QTc) ratio is a reliable index of prolonged ventricular repolarization. OBJECTIVES: In this study, we examined the effects of sodium glucose co-transporters 2 (SGLT2) inhibitors as an add-on therapy to metformin on electrocardiographic indices of ventricular repolarization. METHODS: Electrocardiographic recordings before combination therapy along with three months and six months follow-up of 141 consecutive patients who were switched from monotherapy to combination therapy with two oral agents due to inadequate glycemic control were derived. QT interval (QT), QTc, Tp-e intervals and Tp-e/QT, Tp-e/QTc ratios were calculated and analyzed. RESULTS: After the six month follow-up, there was a significant decrease in the QT interval in patients who were using SGLT2 inhibitors as an add-on therapy to metformin compared to other glucose-lowering agents (373.4 ± 9.9 ms vs. 385.4 ± 12.5 ms, 382.9 ± 11.2 ms; p < 0.001 respectively). Furthermore, Tp-e/QT and Tp-e/QTc ratios were significantly lower in this patient population compared to control groups (0.186 ± 0.023 vs. 0.196 ± 0.021, 0.191 ± 0.017; p < 0.001 and 0.174 ± 0.021 vs. 0.199 ± 0.022, 0.195 ± 0.016; p < 0.001 respectively). CONCLUSIONS: Our data showed that using SGLT2 inhibitors as an add-on therapy to metformin favorably alters ventricular repolarization indices in patients with type 2 diabetes mellitus.
Authors: Paul E Valensi; Nicolas B Johnson; Pierre Maison-Blanche; Fabrice Extramania; Gilbert Motte; Philippe Coumel Journal: Diabetes Care Date: 2002-05 Impact factor: 19.112
Authors: Jesus Castro Hevia; Charles Antzelevitch; Francisco Tornés Bárzaga; Margarita Dorantes Sánchez; Francisco Dorticós Balea; Roberto Zayas Molina; Miguel A Quiñones Pérez; Yanela Fayad Rodríguez Journal: J Am Coll Cardiol Date: 2006-04-17 Impact factor: 24.094
Authors: Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi Journal: N Engl J Med Date: 2015-09-17 Impact factor: 91.245
Authors: Javad Habibi; Annayya R Aroor; James R Sowers; Guanghong Jia; Melvin R Hayden; Mona Garro; Brady Barron; Eric Mayoux; R Scott Rector; Adam Whaley-Connell; Vincent G DeMarco Journal: Cardiovasc Diabetol Date: 2017-01-13 Impact factor: 9.951